Asset
BREXANOLONE
Supernus Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05059600 | phase4 | completed | 2021-10-08 | 2022-07-14 | Supernus Pharmaceuticals, Inc. | A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting |
| NCT02477618 | phase3 | completed | 2015-06-01 | 2017-07-18 | Supernus Pharmaceuticals, Inc. | A Study With SAGE-547 for Super-Refractory Status Epilepticus |
| NCT03665038 | phase3 | completed | 2018-09-07 | 2021-01-08 | Supernus Pharmaceuticals, Inc. | A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD) |
| NCT02614547 | phase2 | completed | 2015-12-15 | 2016-06-22 | Supernus Pharmaceuticals, Inc. | A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression |
| NCT05645432 | phase2 | completed | 2023-05-10 | 2023-11-21 | Supernus Pharmaceuticals, Inc. | An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 211371 | NDA | SAGE THERAPEUTICS LLC A WHOLLY OWNED SUB OF SUPERNUS PHARMACEUTICALS INC |
Marketed products (1)
- ZULRESSO